Skip to main content
Publication, Part of

Prescribing for Diabetes in England - 2005/06 to 2012/13

Official statistics
Publication Date:
Geographic Coverage:
Geographical Granularity:
Country, Primary Care Trusts, Clinical Commissioning Groups, Primary Care Organisations
Date Range:
01 Apr 2005 to 31 Mar 2013


This report is the latest in a series of publications on diabetes by The Health and Social Care Information Centre. It covers the period 2005-06 to 2012-13.


  • In the financial year 2012-13 there were 42.5 million items prescribed for diabetes (BNF section 6.1) at a net ingredient cost of £764.1 million.  This was a 4.7 per cent (1.9 million) rise in the number of items, from 40.6 million in 2011-12, and a 0.5 per cent (£3.8 million) rise in the net ingredient cost, from £760.3 million in 2011-12. In comparison, overall prescribing costs fell between 2011-12 and 2012-13 by 3.9 per cent.
  • Prescribing for diabetes accounted for 4.3 per cent of total items and 9.3 per cent of the total cost of prescribing in 2012-13, compared with 4.2 per cent and 8.9 per cent respectively in 2011-12, and 3.8 per cent and 6.6 per cent respectively in 2005-06.
  • Over the period 2005-06 to 2012-13 there was an increase in the number of items for diabetes of 56.9 per cent (15.4 million) and in net ingredient cost of 48.7 per cent (£250.2 million). In 2005-06 there were 27.1 million items at a cost of £513.9 million. This growth compares with a growth of 37.4 per cent in items and 6.6 per cent for cost of all prescribing over the same period.
  • In 2012-13 there were 6.2 million insulin items (BNF 6.1.1), representing 14.6 per cent of all items prescribed for diabetes, prescribed at a net ingredient cost of £320.0 million.  Compared with the previous financial year this was an increase of 2.6 per cent in the number of items from 6.1 million and a 1.7 per cent increase in net ingredient cost from £314.7 million. Human analogue insulins were the most commonly prescribed form of insulin.
  • In 2012-13 there were 29.7 million items prescribed for Antidiabetic drugs (BNF 6.1.2), representing 69.8 per cent of all items for diabetes, at a net ingredient cost of £273.0 million.  This was an increase of 5.9 per cent in the number of items and a 2.9 per cent decrease in net ingredient cost compared to 2011-12 (when there were 28.0 million Antidiabetic drug items prescribed at a net ingredient cost of £281.0 million).  Since 2005-06, items and net ingredient cost of Antidiabetic drugs have increased by 83.9 per cent and 86.0 per cent respectively.

Administrative Sources

NHS BSA, Quality and Outcomes Framework,ePACT, QOF, NDA


Related Links

Last edited: 27 June 2018 9:32 am